PERNIX THERAPEUTICS HLDGS IN's ticker is PTX and the CUSIP is 71426V108. A total of 114 filers reported holding PERNIX THERAPEUTICS HLDGS IN in Q2 2015. The put-call ratio across all filers is 686.00 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2016 | $84,000 | +2700.0% | 135,144 | +1703.4% | 0.00% | – |
| Q2 2016 | $3,000 | -99.7% | 7,494 | -99.3% | 0.00% | – |
| Q1 2016 | $1,174,000 | -66.3% | 1,117,822 | -5.4% | 0.00% | -100.0% |
| Q4 2015 | $3,486,000 | -45.2% | 1,181,604 | -41.4% | 0.00% | -50.0% |
| Q3 2015 | $6,367,000 | -36.1% | 2,014,955 | +19.7% | 0.00% | 0.0% |
| Q2 2015 | $9,964,000 | -33.9% | 1,683,024 | +19.4% | 0.00% | -50.0% |
| Q1 2015 | $15,074,000 | +16.2% | 1,410,141 | +2.1% | 0.00% | +33.3% |
| Q4 2014 | $12,971,000 | +112.7% | 1,381,348 | +74.0% | 0.00% | +50.0% |
| Q3 2014 | $6,097,000 | -17.1% | 793,867 | -3.1% | 0.00% | 0.0% |
| Q2 2014 | $7,355,000 | +184.7% | 819,013 | +69.7% | 0.00% | +100.0% |
| Q1 2014 | $2,583,000 | +114.2% | 482,722 | +0.9% | 0.00% | – |
| Q4 2013 | $1,206,000 | -10.9% | 478,425 | -3.9% | 0.00% | – |
| Q3 2013 | $1,354,000 | -15.7% | 497,906 | +11.9% | 0.00% | -100.0% |
| Q2 2013 | $1,606,000 | – | 444,791 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 4,800,000 | $15,168,000 | 5.18% |
| Avoro Capital Advisors LLC | 6,004,564 | $18,974,000 | 4.93% |
| DG Capital Management, LLC | 695,808 | $2,199,000 | 2.56% |
| ACUTA CAPITAL PARTNERS, LLC | 1,108,719 | $3,504,000 | 2.03% |
| Aisling Capital LLC | 2,010,000 | $6,352,000 | 1.12% |
| Broadfin Capital, LLC | 6,090,829 | $19,247,000 | 1.07% |
| KOPP INVESTMENT ADVISORS LLC | 375,293 | $1,186,000 | 0.64% |
| SEARLE & CO. | 172,500 | $545,000 | 0.56% |
| Elk Creek Partners, LLC | 1,864,515 | $5,892,000 | 0.48% |
| WALL STREET ASSOCIATES | 696,300 | $2,200,000 | 0.42% |